Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $47
Morgan Stanley analyst Matthew Harrison maintains AlloVir (NASDAQ:ALVR) with a Overweight and lowers the price target from $50 to $47.
AlloVir Q2 EPS $(0.60) Up From $(4.43) YoY
AlloVir (NASDAQ:ALVR) reported quarterly losses of $(0.60) per share. This is a 86.46 percent increase over losses of $(4.43) per share from the same period last year.
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)
Stocks That Hit 52-Week Lows On Thursday
During the morning session on Thursday, 152 stocks hit new 52-week lows.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 158 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET on Thursday, 16 companies hit new 52-week lows.
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)